Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate
US11795236B2 · kind B2 · utility
2Cited by
20References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2018 |
| Grant date | Oct 24, 2023 |
| Priority date | — |
| Expiry date | Aug 4, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(═O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(═O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.